Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study
NCT ID: NCT02192996
Last Updated: 2014-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
5 participants
INTERVENTIONAL
2012-12-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enteral Feeding and Early Gut Colonization of Preterm Infants
NCT02502916
Probiotics Supplementation in Premature Infants
NCT01379417
Prebiotic in Preterm Infants
NCT03306316
Probiotics and Early Microbial Contact in Preterm Neonates
NCT01454661
Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants
NCT00711633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotics supplementation
Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight \< 1300 g and gestational age \< 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of "Bifidobacterium breve" and "Lactobacillus salivarius" , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10\^9 colony forming units (CFU) per doses of each one of the probiotic bacteria.
Probiotic
blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* preterm infants with gestational age less than 29 weeks
Exclusion Criteria
* chromosomopathies
* congenital infections
* non parental consent
1 Hour
1 Week
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Complutense de Madrid
OTHER
Hospital Universitario La Paz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esperanza Escribano
Medical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Miguel Saenz de Pipaon, PhD. MD.
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario La Paz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario La Paz
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Universidad Complutense Madrid
Identifier Type: OTHER
Identifier Source: secondary_id
HULP3551
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.